Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Chief Medical Officers, The Keystone of Health Tech Innovation

Chief Medical Officers at health technology companies are increasingly central to bridging clinical expertise and technology development, driving adoption and meaningful innovation. EY examines how medical leaders shape strategy, product development, and stakeholder trust within the health tech sector. Their role has evolved beyond compliance and safety into a strategic function that influences commercial success and clinical outcomes.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By Health · AonBrian UrbanDr. Charlie SmithFinthrive
Share

Key takeaways

01

CMOs in health tech serve as the critical link between clinical credibility and technology commercialization.

02

Medical leaders are increasingly involved in product strategy, regulatory navigation, and clinical adoption.

03

The CMO role is evolving into a strategic growth driver, not just a safety or compliance function.

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

In the rapidly evolving world of healthcare technology, Chief Medical Officers (CMOs) are emerging as pivotal figures leading health tech innovation.

Healthcare Rethink's Host Brian Urban took a closer look at CMOs and their roles within the health tech innovation with his recent guest, Dr. Charles Smith MD, the Chief Medical Officer for North America at Aon. The pair discussed the transformative path of healthcare tech and Dr. Smith's journey from a childhood aspiration to be a physician to his current role as a CMO. This discussion offers a unique perspective on the challenges and opportunities in the healthcare sector.

Urban and Smith focused on two primary challenges: the fragmented nature of healthcare in the U.S. and the environmental and lifestyle issues impacting health. Dr. Smith emphasized the need for more integrated care systems and addressed the rising obesity rates and their subsequent health implications.

Dr. Smith emphasized the need for more integrated care systems and addressed the rising obesity rates and their subsequent health implications.

Innovation, particularly in the gene therapy and cancer treatment domains, has seen remarkable strides. Dr. Smith applauded the rapid advancements made during the COVID-19 pandemic, from vaccine development to antiviral treatments. He also touched upon Aon's role in the healthcare landscape, emphasizing the importance of aligning innovations with client needs and ensuring they drive meaningful change.

CMOs like Dr. Smith are at the forefront, ensuring that technological advancements align with patient needs, improving outcomes, and shaping the future of healthcare.

In essence, as healthcare continues to evolve, CMOs like Dr. Smith are at the forefront, ensuring that technological advancements align with patient needs, improving outcomes, and shaping the future of healthcare.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

H
Health

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

OpenAI’s ChatGPT for Healthcare is getting wired into Epic

OpenAI’s ChatGPT for Healthcare is getting wired into Epic

ChatGPT for Healthcare can now read from Epic. UCSF Health is piloting the read-only integration, according to Fierce Healthcare and Becker’s Hospital Review. For CIOs, the work is permissions, auditability, and clinical validation in Epic workflows.

  • 01The “read-only” label doesn’t remove governance work, it moves it to permissions mapping, audit logs, and connector scope design inside Epic-supported workflows.
  • 02OpenAI’s published clinician review results (99.1% rated safe across 4,363 ratings) are a useful benchmark, but they still need local validation on your own note templates, meds workflows, and specialty mix.

Sep 7, 2026

The EU’s MDR delay buys time, but it won’t clear your commissioning bottleneck

The European Commission backed extending EU MDR transition deadlines to December 2027 and December 2028, Medical Design & Outsourcing reported. It buys time, not ramp-up capacity. Design News cites digital commissioning and machine digital twins to cut “power-on” surprises and speed validation and operator training.

  • 01If an EU portfolio includes Class III, December 2027 is now the planning anchor, but the internal gating item may shift to validation capacity and automation readiness, not paperwork.
  • 02Digital commissioning is becoming a procurement spec, not a buzzword, because it lets teams run DFM/DFA learning loops before hardware is built, which Design News notes is meant to reduce machine power-on surprises.

Sep 5, 2026

HCA’s Q1 was not about volume. It was about coverage and collecting cash

HCA Healthcare reaffirmed 2026 guidance after Q1 weather and a muted respiratory season cut adjusted EBITDA by about $180 million, according to HealthLeaders and Fierce Healthcare. Payer mix shifted fast. Exchange admissions fell about 15% and uninsured admissions rose about 16%, Fierce reported.

  • 01A mild flu season can be a margin event: HCA tied a 42% drop in respiratory admissions to a roughly $180M adjusted EBITDA hit (HealthLeaders, Fierce Healthcare).
  • 02The 2026 risk is sliding from demand to coverage: HCA cited a $600M–$900M full-year EBITDA headwind from exchange-related changes, with $150M already in Q1 (HealthLeaders, Fierce Healthcare).
  • 03Supplemental payments are becoming an operating capability, not a windfall: HCA said Q1 Medicaid program net benefit was about $200M vs $80M expected (HealthLeaders, Fierce Healthcare), putting state-by-state reimbursement strategy on the CFO’s critical path.

Sep 5, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

H
Health

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512